Chronic obstructive pulmonary disease: emerging therapies.
Despite the high prevalence of and mortality from chronic obstructive pulmonary disease, extensive research on the underlying pathophysiology and specific therapeutics for this disease is, relatively, in its infancy. Several novel molecular targets are being investigated as potential treatments for the disease. The most exciting new class of compounds is the phosphodiesterase 4 inhibitors; Ariflo (SB 207499)-a member of this class, and the most advanced in development (Phase III)-was reported recently to have significant clinical efficacy in patients with chronic obstructive pulmonary disease. Phosphodiesterase 4 inhibitors, such as Ariflo, possibly represent the most important advance in pulmonary medicine in recent years.
Hay
D W
DW
Department of Pulmonary Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA. douglas_w_hay@sbphrd.com
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D018925:Chemokines / Q000037:antagonists & inhibitors; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D016232:Endothelins / Q000037:antagonists & inhibitors; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D015394:Molecular Structure; D011480:Protease Inhibitors / Q000627:therapeutic use; D011976:Receptors, Muscarinic / Q000378:metabolism; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors; D048051:p38 Mitogen-Activated Protein Kinases
D018925:Chemokines; D016232:Endothelins; D011480:Protease Inhibitors; D011976:Receptors, Muscarinic; D018039:Receptors, Tachykinin; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4